---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078665"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:57:56.052145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025

## Summary
- Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.
- Basic EPS of $0.51; diluted EPS loss of $1.00.
- R&D expenses $5.8M (down $0.7M YoY); G&A expenses $3.1M (up $2.4M due to merger costs).
- Cash, equivalents, and short-term investments $41.0M as of June 30, 2025; runway into Q4 2026.
- REVERT IPF Phase 2 trial fully enrolled; topline data expected Q4 2025. IND for TTI-109 submitted to FDA in June 2025.

## SEC filing metadata
- accession: 0001104659-25-078665
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/0001104659-25-078665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078665
- JSON: https://secwatch.observer/filing/0001104659-25-078665.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.